Rainbow Children's Medicare Approves FY26 Results, Re-appoints Key Directors, Declares Dividend
Rainbow Children's Medicare approved FY26 audited results and recommended a final dividend of ₹3.5 per share. The 28th AGM is on July 29, 2026, with July 21, 2026, as the record date. Dr. Ramesh Kancharla and Dr. Dinesh Kumar Chirla were re-appointed as CMD and Whole-Time Director, respectively, for five years from August 11, 2026. Independent Directors Mr. Santanu Mukherjee and Ms. Sundari R. Pisupati were also re-appointed.
The re-appointment of key management and the declaration of a dividend are significant corporate actions that can impact investor confidence and company strategy.
The announcement includes the approval of financial results, recommendation of a final dividend, and re-appointment of key management personnel, all positive developments for the company.
Rainbow Children's Medicare Limited announced the outcome of its Board Meeting held on May 23, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company also recommended a final dividend of ₹3.5 per equity share (35%) for the Financial Year 2025-26, subject to shareholder approval at the upcoming AGM.
The 28th Annual General Meeting (AGM) is scheduled to be convened on Wednesday, July 29, 2026, through Video Conferencing/Other Audio-Visual Means. Tuesday, July 21, 2026, has been fixed as the Record Date for the payment of the final dividend and for the AGM purposes.
Further, the Board approved the re-appointment of key management personnel. Dr. Ramesh Kancharla has been re-appointed as Chairman and Managing Director for a period of five years from August 11, 2026, to August 10, 2031. Dr. Dinesh Kumar Chirla has also been re-appointed as Whole Time Director for a similar five-year term from August 11, 2026, to August 10, 2031. Both re-appointments are subject to member approval at the AGM.
Additionally, Mr. Santanu Mukherjee has been re-appointed as an Independent Director for a second term of five years from October 22, 2026, to October 21, 2031. Ms. Sundari R. Pisupati has been re-appointed as an Independent Director for a second term of five years from September 16, 2026, to September 15, 2031. These re-appointments are also subject to shareholder approval at the AGM.
The Board also approved the re-appointment of M/s. Lavanya & Associates LLP as the Cost Auditors for the Financial Year 2026-27. The Board Meeting commenced at 4:45 PM and concluded at 6:30 PM.
What to do with a filing like this
Rainbow Childrens Medicare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Rainbow Childrens Medicare Limited. Read the original for the full detail.